Pharmacokinetics of azithromycin in trachoma patients: Serum and tear levels

Ophthalmology

Volumn 105, Issue 4, 1998, Pages 658-661

  Karcioglu, Zeynel A ^a   El Yazigi, A ^b   Jabak, M H ^a   Choudhury, A H ^c   Ahmed, W S ^a  

^a KING KHALED EYE SPECIALIST HOSPITAL   (Saudi Arabia)

^b KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

^c Trachoma Control Program   (Saudi Arabia)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN;

ARTICLE; CHILD; CHLAMYDIA TRACHOMATIS; CLINICAL ARTICLE; DRUG BLOOD LEVEL; DRUG EFFICACY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LACRIMAL FLUID LEVEL; MINIMUM INHIBITORY CONCENTRATION; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SCHOOL CHILD; TRACHOMA;

EID: 0031893702     PISSN: 01616420     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0161-6420(98)94020-9     Document Type: Article

References (17)

1. Peters DH, Friedel HA, McTavish D, Azithromycin. A review of its antimicrobial activity, pharmacokinetic properties and clinical efficacy. Drugs 1992;44:750-99.
2. Williams JD. Spectrum of activity of azithromycin. Eur J Clin Microbiol Infect Dis 1995;10:813-20.
3. Foulds G, Shepard RM, Johnson RB. The pharmacokinetics of azithromycin in human serum and tissues. J Antimicrob Chemother 1990;25 Suppl A:73-82.
4. Gladue RP, Bright GM, Isaacson RE, Newborg MF. In vitro and in vivo uptake of azithromycin (CP-62, 993) by phagocytic cells: possible mechanism of delivery and release at sites of infection. Antimicrob Agents Chemother 1989;33:277-82.
5. Girard AE, Girard D, English AR, et al. Pharmacokinetic and in vivo studies with azithromycin (CP-62,993), a new macrolide with extended half-life and excellent tissue distribution. Antimicrob Agents Chemother 1987;31:1948-54.
6. Foulds G, Chan KH, Johnston JT, et al. Concentrations of azithromycin in human tonsillar tissue. Eur J Clin Microbiol Infect Dis 1991;10:853-6.
7. Fiese EF, Steffen SH. Comparison of the acid stability of azithromycin and erythromycin A. J Antimicrob Chemother 1990;25 Suppl A:39-47.
8. Dawson CR, Jones BR, Tarizzo ML. Guide to trachoma control in programmes for the prevention of blindness. Geneva: World Health Organization; Albany, NY: WHO Publications Centre USA [distributor], 1981.
9. Tarizzo ML. Chemotherapy of trachoma. WHO Chron 1972;26:99-101.
10. Bailey RL, Arullendran P, Whittle HC, Mabey DC. Randomised controlled trial of single-dose azithromycin in treatment of trachoma. Lancet 1993;342:453-6.
11. Tabarra KF, Abu-El-Asrar AM, Al-Omar O, et al. Single-dose azithromycin in the treatment of trachoma. A randomized, controlled study. Ophthalmology 1996;103:842-6.
12. O'Day DM, Head WS, Foulds G, et al. Ocular pharmacokinetics of orally administered azithromycin in rabbits. J Ocul Pharmacol 1994;10:633-41.
13. Slaney L, Chubb H, Ronald A, Brunham R. In vitro activity of azithromycin, erythromycin, ciprofloxacin, and norfloxacin against Neisseria gonorrhoeae, Haemophilus ducreyi, and Chlamydia trachomatis. J Antimicrob Chemother 1990;25 Suppl A:1-5.
14. Scieux C, Bianchi A, Chappey B, et al. In-vitro activity of azithromycin against Chlamydia trachomatis. J Antimicrob Chemother 1990;25 Suppl A:7-10.
15. Malaty R, Zaki S, Said ME, et al. Extraocular infections in children in areas with endemic trachoma. J Infect Dis 1981;143:853.
16. Tabarra KF. Trachoma and inclusion conjunctivitis. In: Tabarra KF, Hyndiuk RA, eds. Infections of the Eye, 2nd ed. Boston: Little-Brown, 1996;433-51.
17. Retsema J, Girard A, Schelkly W, et al. Spectrum and mode of action of azithromycin, (CP-62,993), a new 15-membered-ring macrolide with improved potency against gram-negative organisms. Antimicrob Agents Chemother 1987;31:1939-47.